rosuvastatin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome
Trial Timeline
Dec 1, 2008 → Mar 1, 2010
NCT ID
NCT00815659About rosuvastatin
rosuvastatin is a approved stage product being developed by AstraZeneca for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00815659. Target conditions include Metabolic Syndrome.
What happened to similar drugs?
18 of 20 similar drugs in Metabolic Syndrome were approved
Approved (18) Terminated (4) Active (2)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160745 | Phase 2 | Completed |
| NCT04846231 | Phase 2 | Completed |
| NCT02561845 | Pre-clinical | Withdrawn |
| NCT02484027 | Approved | UNKNOWN |
| NCT02077257 | Approved | UNKNOWN |
| NCT01837823 | Phase 2 | Completed |
| NCT01490398 | Approved | Completed |
| NCT01364220 | Phase 3 | Terminated |
| NCT00815659 | Approved | Completed |
| NCT00747149 | Approved | Completed |
| NCT00473655 | Approved | Completed |
| NCT00335699 | Approved | Completed |
| NCT00184951 | Phase 2 | Completed |
| NCT00240305 | Phase 3 | Completed |
| NCT00176332 | Phase 2 | Completed |
| NCT00228514 | Phase 3 | Completed |
| NCT00240266 | Phase 3 | Completed |
| NCT00241488 | Phase 3 | Completed |
| NCT00660764 | Pre-clinical | Completed |
| NCT00239681 | Phase 3 | Terminated |
Competing Products
20 competing products in Metabolic Syndrome